Abstract:Background: As one of the most common malignancy, lung adenocarcinoma (LUAD) is characterized by low 5-year survival rate. This research aimed to investigate the effects of ribonucleotide reductase regulatory subunit M2 (RRM2) on malignant biological behaviors and activation of cGAS/STING pathway. We also explored the synergistic sensitization mechanisms of RRM2 and radiotherapy. Methods: Bioinformatic tools were used to evaluate the clinical significance of RRM2 in LUAD patients. The roles of RRM2 in malignant phenotype and DNA damage in LUAD cells were investigated with cell proliferation, colony formation, immunofluorescence, modified Boyden chamber and comet assays. The mouse models were used to evaluate the biological significance of RRM2 in vivo. Cytotoxic T cell infiltration was evaluated via flow cytometric analysis and immunohistochemistry staining in C57BL/6 mice. We also explored the synergistic effects of RRM2 silencing and radiation on LUAD cells with apoptosis assay and immunoblotting in vitro. Results: Bioinformatic analysis revealed that RRM2 had diagnostic values for LUAD patients. Higher levels of RRM2 predicted worse prognosis. RRM2 silencing inhibited LUAD cell proliferation, invasion and migration. RRM2 knockdown induced S phase arrest and DNA damage. RRM2 silencing induced cyclic GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) pathway, and the downstream targets were regulated in a STING-dependent manner. Knockdown of RRM2 suppressed tumor growth in the xenograft tumor models. RRM2 deficiency increased CD8 + T cells in the tumor tissues and spleens. Furthermore, RRM2 silencing had synergistic effects with radiation on inhibiting cell proliferation and promoting apoptosis. Meanwhile, this combination promoted the activation of cGAS/STING signaling pathway synergistically, and simultaneously increased expression of IFNβ, CCL5 and CXCL10. Conclusion: Our results demonstrated that RRM2 silencing had anti-tumor values and activated the cGAS/STING signaling pathway. RRM2 silencing increased CD8 + T cells infiltration. RRM2 silencing cooperated with radiation to inhibit LUAD cell proliferation, promote apoptosis and enhance the activation of cGAS/STING signaling pathway. RRM2 could be a promising target for tumor regression through cancer immunotherapy in LUAD.

SMC2 knockdown inhibits malignant progression of lung adenocarcinoma by upregulating BTG2 expression

MTHFD2 Promotes Tumorigenesis and Metastasis in Lung Adenocarcinoma by Regulating AKT/GSK‐3β/β‐catenin Signalling

Abstract 5426: SMC2 Orchestrates Non-Small Cell Lung Cancer Proliferation, Invasion, and Metastasis by Modulating the ERK/AKT/NF-κB Pathways

CBX2 and EZH2 Cooperatively Promote the Growth and Metastasis of Lung Adenocarcinoma

RRM2 silencing suppresses malignant phenotype and enhances radiosensitivity via activating cGAS/STING signaling pathway in lung adenocarcinoma

Overexpression of MYBL2 Promotes Proliferation and Migration of Non-Small-cell Lung Cancer Via Upregulating NCAPH

CCT6A Suppresses SMAD2 and Promotes Prometastatic TGF-β Signaling

Identification ofLBX2as a novel causal gene of lung adenocarcinoma

Histone Lysine Methyltransferase SETDB2 Suppresses NRF2 to Restrict Tumor Progression and Modulates Chemotherapy Sensitivity in Lung Adenocarcinoma

MiR-579 Inhibits Lung Adenocarcinoma Cell Proliferation and Metastasis via Binding to CRABP2

BZW2 promotes malignant progression in lung adenocarcinoma through enhancing the ubiquitination and degradation of GSK3β

SGO2 as a Prognostic Biomarker Correlated with Cell Proliferation, Migration, Invasion, and Epithelial-Mesenchymal Transition in Lung Adenocarcinoma

CircSFMBT2 Plays an Oncogenic Role in Lung Adenocarcinoma Depending on the miR-1305/SALL4 Axis

The Effects and Mechanisms of SLC34A2 in Tumorigenesis and Progression of Human Non-Small Cell Lung Cancer

Knockdown of GTF2E2 Inhibits the Growth and Progression of Lung Adenocarcinoma Via RPS4X in Vitro and in Vivo

Knockdown of SUMO-activating enzyme subunit 2 (SAE2) suppresses cancer malignancy and enhances chemotherapy sensitivity in small cell lung cancer

TOP2A Promotes Lung Adenocarcinoma Cells' Malignant Progression and Predicts Poor Prognosis in Lung Adenocarcinoma.

PLEK2 promotes lung adenocarcinoma progression via activating the PI3K/AKT signaling pathway through SPC25 Running title: PLEK2 promotes LUAD via SPC25/PI3K/AKT axis

B-Cell Translocation Gene 2 Upregulation is Associated with Favorable Prognosis in Lung Adenocarcinoma and Prolonged Patient Survival

BTG2 and SerpinB5, a novel gene pair to evaluate the prognosis of lung adenocarcinoma

PLEK2 activates the PI3K/AKT signaling pathway to drive lung adenocarcinoma progression by upregulating SPC25